细胞周期蛋白依赖性激酶4/6抑制的转录组 - Suppr

Suppr

超能文献

The transcriptome of CDK4/6 inhibition.

作者信息

Knudsen Erik S, Witkiewicz Agnieszka K

机构信息

Department of Medicine, ,, University of Arizona, Tucson, AZ 85721, USA.

出版信息

Aging (Albany NY). 2017 Aug 30;9(8):1859-1860. doi: 10.18632/aging.101285.

DOI:10.18632/aging.101285

PMID:28860413

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5611978/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd46/5611978/5083d7dffbdb/aging-09-1859-g001.jpg

相似文献

The transcriptome of CDK4/6 inhibition.细胞周期蛋白依赖性激酶4/6抑制的转录组

Aging (Albany NY). 2017 Aug 30;9(8):1859-1860. doi: 10.18632/aging.101285.

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.CDK4/6抑制剂的生物学特异性：剂量反应关系、体内信号传导及复合反应特征

Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.

Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.细胞周期蛋白依赖性激酶 4/6 抑制剂在乳腺癌中的应用：帕博西尼、瑞博西尼和阿贝西利。

Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24.

CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.CDK4/6 抑制作为乳腺癌的治疗策略：帕博西利、瑞博西利和阿贝西利。

Semin Oncol. 2017 Dec;44(6):395-403. doi: 10.1053/j.seminoncol.2018.03.006. Epub 2018 Mar 26.

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.乳腺癌中环磷酰胺依赖性激酶 4/6 抑制剂相关毒性和药物相互作用的临床处理：实用注意事项和建议。

Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13.

Role of cyclin-dependent kinase 4/6 inhibitors in the current and future eras of cancer treatment.细胞周期蛋白依赖性激酶4/6抑制剂在当前及未来癌症治疗时代的作用

J Oncol Pharm Pract. 2019 Jan;25(1):110-129. doi: 10.1177/1078155218770904. Epub 2018 May 4.

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.乳腺癌中 CDK4/6 抑制剂耐药的分子机制：综述。

Int J Cancer. 2019 Sep 1;145(5):1179-1188. doi: 10.1002/ijc.32020. Epub 2019 Jan 7.

CDK4/6 Inhibitors Expand the Therapeutic Options in Breast Cancer: Palbociclib, Ribociclib and Abemaciclib.CDK4/6 抑制剂拓展乳腺癌治疗选择：哌柏西利、瑞博西利和阿贝西利。

BioDrugs. 2019 Apr;33(2):125-135. doi: 10.1007/s40259-019-00337-6.

Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.乳腺癌治疗性 CDK4/6 抑制的作用机制。

Semin Oncol. 2017 Dec;44(6):385-394. doi: 10.1053/j.seminoncol.2018.01.006.

CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers.CDK4/6 和自噬抑制剂协同诱导 Rb 阳性细胞质 cyclin E 阴性癌症衰老。

Nat Commun. 2017 Jun 27;8:15916. doi: 10.1038/ncomms15916.

引用本文的文献

Firing of Replication Origins Is Disturbed by a CDK4/6 Inhibitor in a pRb-Independent Manner.复制原点的激发被一种 CDK4/6 抑制剂以一种不依赖 pRb 的方式扰乱。

Int J Mol Sci. 2023 Jun 25;24(13):10629. doi: 10.3390/ijms241310629.

The E2F Pathway Score as a Predictive Biomarker of Response to Neoadjuvant Therapy in ER+/HER2- Breast Cancer.E2F 通路评分作为 ER+/HER2- 乳腺癌新辅助治疗反应的预测性生物标志物。

Cells. 2020 Jul 8;9(7):1643. doi: 10.3390/cells9071643.

本文引用的文献

CDK4/6 inhibition triggers anti-tumour immunity.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制可触发抗肿瘤免疫。

Nature. 2017 Aug 24;548(7668):471-475. doi: 10.1038/nature23465. Epub 2017 Aug 16.

Oncotarget. 2017 Jul 4;8(27):43678-43691. doi: 10.18632/oncotarget.18435.

The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies.细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制剂的奇闻：作用机制、耐药性及联合策略

Trends Cancer. 2017 Jan;3(1):39-55. doi: 10.1016/j.trecan.2016.11.006.

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor-Positive Breast Cancer.NeoPalAna研究：新辅助哌柏西利（一种细胞周期蛋白依赖性激酶4/6抑制剂）联合阿那曲唑治疗临床2期或3期雌激素受体阳性乳腺癌

Clin Cancer Res. 2017 Aug 1;23(15):4055-4065. doi: 10.1158/1078-0432.CCR-16-3206. Epub 2017 Mar 7.

Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.确定与雌激素受体阳性/人表皮生长因子受体2阴性（ER+/HER2-）乳腺癌相关的对细胞周期蛋白依赖性激酶4/6（CDK4/6）抑制的转录和生物学反应。

Oncotarget. 2016 Oct 25;7(43):69111-69123. doi: 10.18632/oncotarget.11588.

Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6.通过延长抑制CDK4/6诱导维莫非尼耐药黑色素瘤的治疗性衰老

Cancer Res. 2016 May 15;76(10):2990-3002. doi: 10.1158/0008-5472.CAN-15-2931. Epub 2016 Mar 17.

Targeting CDK4 and CDK6: From Discovery to Therapy.靶向细胞周期蛋白依赖性激酶4和6：从发现到治疗

Cancer Discov. 2016 Apr;6(4):353-67. doi: 10.1158/2159-8290.CD-15-0894. Epub 2015 Dec 11.

Proteomic analysis of pRb loss highlights a signature of decreased mitochondrial oxidative phosphorylation.视网膜母细胞瘤蛋白缺失的蛋白质组学分析突出了线粒体氧化磷酸化降低的特征。

Genes Dev. 2015 Sep 1;29(17):1875-89. doi: 10.1101/gad.264127.115. Epub 2015 Aug 27.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验